

DOCKET NO.: 283625US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

GROUP: 1627

Antoni TORRENS JOVER, et al.

SERIAL NO: 10/566,402

EXAMINER: RAMACHANDRAN,
UMAMAHESWARI

FILED: July 5, 2006

FOR: ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND
WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6
RECEPTOR AFFINITY

RESTRICTION RESPONSE

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

In response to the Restriction Requirement dated December 02, 2009, Applicants provisionally elect the following species, for examination purposes only:

- (1) 2-(4-(8-methyl-2-oxo-2,4-dihydro-1H-benzo[d][1,3]oxazin-1-yl)piperidin-1-yl) N-(9-oxo-9H-fluoren-3-yl)acetamide hydrochloride as a compound binding NPY5 receptor (at least claims 1 - 45 readable thereon);
- (2) 5-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)naphthalene-2-sulfonamide as a compound binding 5-HT6 receptor (at least claims 1 - 45 readable thereon); and
- (3) regulation of appetite as the disease (at least claims 7, 9 and 34 - 45 readable thereon).

Remarks/Arguments begin on page 2 of this paper.